Insys reaffirms Q2 revenue guidance


Insys Therapeutics (INSY) reaffirms its Q2 revenue guidance for Subsys (Fentanyl Sublingual Spray). Sales should exceed $52M. This represents a yoy increase of 181%. The company will report its results for the quarter on August 12 before the open.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs